Eduardo J. Pennella

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Mark A. Socinski, Edward B. Garon et al. · Journal of Clinical Oncology · 2013 · 372 citations · Full text

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Hope S. Rugo, Abhijit Barve, Cornelius F. Waller et al. · JAMA · 2016 · 142 citations · Full text

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Philip Bonomi, Mark A. Socinski et al. · Clinical Lung Cancer · 2009 · 67 citations

Maintenance Bevacizumab, Medicine, Treatment Rationale +10

Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer

Waldo Ortuzar, Nasser H. Hanna, Eduardo J. Pennella et al. · Clinical Lung Cancer · 2011 · 30 citations

Primary Site, Neuro-oncology, Brain Metastases +9

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim

Cornelius F. Waller, Renger G. Tiessen, Tracey E. Lawrence et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 30 citations · Full text

Pharmacological Study, Pegfilgrastim Biosimilar, Medicine +4